It’s set to report second-quarter earnings on Thursday as the corporate sits on the point of an unsure transition into the industrial Covid-19 vaccine market, with questions looming over how a lot demand stays for the vaccines three years after their launch.
Analysts count on
(Inventory ticker: MRNA) reported a lack of $3.93 per share for the quarter, on income of simply $308 million, in line with FactSet. The corporate achieved revenues of $4.7 billion in the identical quarter final yr.
Whereas the Covid-19 vaccine has develop into one of many best-selling medication of all time, with $18.4 billion in gross sales in 2022, Moderna has no different marketed merchandise. The corporate mentioned it expects Covid-19 vaccine gross sales of at the least $5 billion in 2023. Analysts count on $7.1 billion in gross sales this yr, in line with FactSet.
Moderna shares are down practically 40% this yr, as an alternative
Normal & Poor’s 500
Earlier this yr, Moderna mentioned it anticipated Covid-19 vaccine gross sales of between $200 million and $300 million within the second quarter. Industrial gross sales of the vaccine are anticipated to start this fall, when the corporate will launch an up to date model of the vaccine. For the reason that first injections got in late 2020, all Covid-19 vaccines in the US have been paid for by the federal authorities. That ended earlier this yr; The federal government is at present working by its remaining provides.
Moderna’s Covid-19 vaccine competitor
(Inventory ticker: PFE), in its earnings presentation on Tuesday, burdened the uncertainty within the US Covid-19 vaccine market, saying that uptake up to now this yr was decrease than anticipated, however that Pfizer’s market share was barely bigger than anticipated. Pfizer mentioned it might make value cuts if gross sales of its Covid-19 vaccine and therapeutics fall in need of expectations by the top of the yr.
The scenario in Moderna is totally different. The Covid-19 vaccine, Spikevax, was the corporate’s first product marketed. Whereas it has a large pipeline, together with numerous late-stage packages, no product launches are anticipated this yr.
Vital Modena pipeline packages embody a vaccine for respiratory syncytial virus, which may very well be launched in 2024 and would compete with new RSV vaccines from Pfizer and
(GSK). The corporate can also be anticipating new knowledge on its messenger RNA-based flu vaccine later this yr, and it not too long ago launched a Part 3 research in collaboration with
(MRK) her promising Most cancers remedy, mRNA-4157.
Moderna plans to carry investor Name at 8 a.m. on a Thursday to debate the monetary outcomes.
Write to Josh Nathan Kazis at email@example.com